Novo Nordisk's stock price rises by nearly 10% after results for new obesity drug

Patients in the study received increasing doses of Amycretin, a drug that mimics the same gut hormone as Wegovy. The company behind the blockbuster obesity drug Wegovy and the diabetes medication Ozempic has been working for some time to develop the next generation of medications that it hopes will accelerate weight loss, provide broader health benefits, and reduce side effects at the same time. Novo Nordisk successfully completes Phase 1b/2a study of subcutaneous Amycretin in overweight or obese individuals Novo Nordisk (i) today (January 24,...